Clinical Trial Update: Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Zevalin (ibritumomab tiuxetan) versus no treatment as consolidation in follicular lymphoma patients who achieved partial or complete rem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Bayer | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED